Business
FY25 Preliminary Results to 31 December 2025
Fevertree Drinks plc reported positive strategic progress for the year ending December 31, 2025, with Adjusted Fever-Tree brand revenue increasing by 4% year-on-year at constant currency to £372.7 million, driven by a 5% acceleration in the second half. The company's diversification strategy is gaining scale, with 45% of Group revenue now generated from products beyond tonic. Despite a 16% year-on-year decrease in Adjusted EBITDA to £42.4 million, partly due to the US transition costs, the company completed a £100 million share buyback and has a further £30 million buyback in progress. The company remains comfortable with market expectations for 2026, with strong US brand momentum and continued market share gains in Europe. A provision of £2.8 million has been made for a potential UK Extended Producer Responsibility Levy. Disclaimer*
About this update from Fevertree Drinks Plc
[{"type":"text","content":"\n\n\nFevertree Drinks plc\n\nFY25 Preliminary Results to 31 December 2025\n \nPositive strategic progress during the year\nComfortable with market expectations for 2026\nHighlights\n· Fever-Tree brand revenue increased 4% year-on-year (constant currency), accelerating to +5% in H2, reflecting improving momentum across regions and further market share gains.\n· Diversification gaining scale, with 45% of Group revenue now generated from products beyond tonic, broadening Fever-Tree's relevance across a wider range of adult socialising occasions.\n· Strong US brand momentum maintained throughout the Molson Coors transition, establishing a scalable platform for accelerated growth in 2026.\n· UK revenue down 2% but performance improved in the second half, driven by a strong Off-Trade performance\n· Europe delivered continued market share gains in premium mixers, with Ginger Beer a standout performer, delivering double-digit growth and reinforcing category leadership across the region.\n· Adjusted EBITDA includes a post period end adjustment to provide for a potential incremental £2.8m charge relating to the UK Extended Producer Responsibility (\"EPR\") Levy.* Excluding this EPR-related provision, adjusted EBITDA was £45.2m, in line with previous guidance.\n· The Group completed a £100m share buyback, funded by strong operating cash flow, working capital efficiencies and transaction proceeds from the Molson Coors share issue.\n· A further £30 million share buyback is in progress, highlighting our cash generative model.\n \n \n\n\n\n\n£m\n\n\nFY25\n\n\nFY24\n\n\n% YoY\n\n\n% CC\n\n\n\n\nRevenue\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n US\n\n\n131.9\n\n\n128.0\n\n\n3%\n\n\n6%\n\n\n\n\n UK\n\n\n108.4\n\n\n111.1\n\n\n(2%)\n\n\n \n\n\n\n\n Europe (Fever-Tree brand revenue)\n\n\n94.7\n\n\n92.7\n\n\n2%\n\n\n2%\n\n\n\n\n ROW\n\n\n37.7\n\n\n32.2\n\n\n17%\n\n\n22%\n\n\n\n\nTotal Adjusted Fever-Tree Revenue\n\n\n372.7\n\n\n364.0\n\n\n2%\n\n\n4%\n\n\n\n\n GDP brand revenue\n\n\n2.6\n\n\n4.5\n\n\n(42%)\n\n\n(43%)\n\n\n\n\nTotal Adjusted Revenue[1]\n\n\n375.3\n\n\n368.5\n\n\n2%\n\n\n3%\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\nAdjuste...